Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03130764
Title Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Adrian Sacher
Indications
Therapies
Age Groups: senior | adult
Covered Countries

Facility Status City State Zip Country Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field